Week in Review: Cannabis & Psychedelics Industry Highlights

LOS ANGELES – Something shifted last fortnight, and the numbers show it. A cross-border acquisition fight is escalating in public and raising its own price, with hundreds of millions of dollars and an entire European supply chain on the table. Meanwhile, index committees are admitting Cannabis MSOs to their ranks, psychedelics investors are writing nine-figure checks without apology, and federal rescheduling hit another wall. At first glance, it seems like the industry is slowing down. However, the opposite is true – it is accelerating… and compressing. Here’s the full picture.

1.  Curaleaf, Aurora & the Battle for Europe

The biggest story in the room remains Curaleaf’s pursuit of Aurora Cannabis. Curaleaf raised its acquisition bid to US$5.00 per share, an 86% premium over Aurora’s unaffected 30-day volume weighed average price, with a cap price premium reaching 118%. The cash component alone reflects a 33% increase over the original offer. Aurora’s shares moved more than 5% in premarket trading on the announcement. The company has now extended its bid expiry to December 4, 2026.

What makes this fight especially revealing is that Curaleaf upped its offer without Aurora’s cooperation. No due diligence access. No engagement. Aurora’s board has repeatedly rejected the bid, arguing that the company’s EU-GMP certified production infrastructure is undervalued in Curaleaf’s math. They’re not wrong that EU-GMP certification is scarce and strategically irreplaceable. Valuations aside, the central question now is time. Aurora’s leadership must now demonstrate, against the clock, that their multi-year transformation into a high-margin global medical operator produces returns that exceed what Curaleaf is laying on the table.

The regulatory dimension adds another layer. Aurora filed a regulatory complaint against Curaleaf over the hostile bid, and the full weight of that challenge is still being assessed. Meanwhile, Curaleaf continues pushing its international expansion. The company secured Australian regulatory approval for its medical Cannabis inhaler and simultaneously listed in New Zealand. These aren’t unrelated moves. Every piece of Curaleaf’s international footprint strengthens the rationale for folding Aurora’s European assets into a single global operating company.

2.  Index Inclusions & the Signals They Send

Trulieve earned inclusion in the S&P Indices, a meaningful validation for the MSO that has built one of the more disciplined balance sheets in the industry. Trulieve’s inclusion in the S&P Indices reflects its sustained financial performance over time – a factor that index committees reward.

Separately, Curaleaf was added to the FTSE Canada All Cap Index, expanding its reach with Canadian institutional investors at precisely the moment when it is engaged in the most far-reaching corporate maneuver.

3.  MSOs Building Through Deals & Capital Structures

Acquisitions and structured financing continued to reshape the multistate operator tier.

Vireo Growth completed its acquisition of M3 Wellness, adding retail-facing assets to its operational profile. In a separate move, Vireo tied its Ohio promissory note to shares via a put/call agreement, converting debt obligations into an equity instrument – a structuring technique that reduces cash pressure while aligning creditor and shareholder interests.

Green Thumb Industries signaled its own confidence by taking action where it counts most. Again, GTI bet on its own stock through a share repurchase program, simultaneously allocating capital and a public statement about where management believes the company’s valuation stands relative to its intrinsic worth. Buybacks keep rolling in the capital-constrained industry.

Trulieve added another strategic layer by securing an exclusive master licensing agreement with Connected Cannabis, one of the most sought-after premium brands in the country. That agreement gives Trulieve the right to operate the Connected name across its footprint – a brand-licensing play that costs less than a full acquisition while delivering shelf differentiation in a margin-compressed market.

4.  Federal Uncertainty Holds the Room

A DEA administrative law judge stalled adult-use Cannabis rescheduling proceedings, citing process gaps in a government report. The ruling sends the rescheduling process back for procedural correction and extends an already long timeline for an industry that has been waiting on federal clarity since the Biden administration first signaled movement on the issue. Operators who built their capital strategies around rescheduling timelines will need to recalibrate.

Nasdaq’s $5M minimum bid delisting rule remains frozen, offering temporary relief for Cannabis companies trading at compressed share prices, but that protection is not permanent. The freeze buys time, but it doesn’t solve the underlying compliance math.

Ohio moved ahead with new packaging and potency limits for Cannabis products, reflecting the state’s effort to mature its regulatory framework following its transition to adult-use.

5.  Data, Tech & Transparency

Consumer trust continues to intersect with technology infrastructure in ways that operators ignore at their peril. A new study found strong consumer support for state-mandated QR codes on Cannabis products, with shoppers expressing a clear preference for traceable, verifiable product information.

BLAZE rolled out an AI connector for Cannabis dispensaries, expanding PoS intelligence capabilities at the retail layer.

NCS Analytics partnered with the Cannabiz Credit Association on lending data, linking payment behavior records to credit underwriting and building the financial infrastructure Cannabis businesses need to access capital on terms closer to those available in other industries.

6.  Cross-Border Expansion & Retail Dominance

Outside the U.S., Canopy Growth pushed into the UK market as part of a broader European expansion. European medical Cannabis markets are absorbing new entrants at a pace that reflects unmet clinical demand, and the UK entry positions Canopy ahead of what most analysts expect to be a multi-year expansion of legal access across the continent.

In Canada, Canna Cabana extended its lead in retail by the widest margin yet, reinforcing the thesis that retail consolidation in mature Cannabis markets follows the same playbook as convenience and pharmacy.

7.  Psychedelics Capital Accelerates

Two funding rounds confirmed that institutional money is moving into psychedelic therapeutics with real conviction.

Kasvu Therapeutics closed a €30 million raise for next-generation neuroplasticity drugs, targeting the underlying mechanisms of brain adaptability rather than narrow indication-specific treatments.

BetterLife Pharma closed a $100 million offering for its neurological drug pipeline, bringing serious capital firepower to a development-stage company.

On the public policy side, California allocated funding to support psychedelic research for veterans. Vets’ mental health represents one of the most compelling clinical arguments for psychedelic-assisted therapy, and California’s backing, following similar moves at the federal level, keeps the evidence base growing at a rate that regulators can no longer ignore.

A wellness-focused counterpart also emerged. A new guide for menopause and major cannabinoids reflects the expanding consumer base for plant-based therapeutic tools, a segment that is growing faster than most retail analysts projected.

HCN Insight

Taken together, last fortnight’s news pack unfolds into a storyline of the industry sorting itself into tiers at speed. At the top, a small number of MSOs (Curaleaf, Trulieve, GTI) are making capital moves that separate companies with long-term survival strategies from those running on hope. Curaleaf’s escalating Aurora bid is the most visible example – a company spending real money to acquire assets it believes are priced below replacement cost. Whether Aurora’s board holds or folds before December matters less than the broader signal it sends, cross-border consolidation is now the defining strategic play in Cannabis, and operators without a global thesis are already behind.

Federal stagnation on rescheduling continues to separate strong balance sheets from weak ones. The companies that built for a rescheduling tailwind and didn’t plan for delay are now running thin. The Nasdaq freeze helps, but it is a lifeline, not a lifejacket.

Meanwhile, the psychedelics funding wave shows no signs of cooling, and the capital going into neuroplasticity research suggests that the next generation of approved therapeutics may reach far beyond what psilocybin trials have currently framed. The combination of veteran-focused policy support, European market entry, and nine-figure funding rounds points toward a category that is moving from fringe to clinical infrastructure faster than most mainstream investors have priced in.

Here is the question worth sitting with. In the industry this volatile, this politically dependent, and this capital-intensive, who actually survives the next eighteen months, and what do they look like on the other side? The operators making decisive moves right now are writing the answer in real time. The ones waiting for federal clarity may be waiting for a high sign that arrives too late to act on.